The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity.
Dariusz Mirosław KowalskiMagdalena Zaborowska-SzmiSebastian SzmitPiotr JaśkiewiczMaciej KrzakowskiPublished in: Translational lung cancer research (2024)